The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 1, 2009, Pages 81-86

  Gleave, Martin ^a   Klotz, Laurence ^b   Taneja, Samir S ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hormone ablation; Hormone therapy; Intermittent androgen suppression; Metastatic disease; Prostate cancer; Therapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CASTRATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LYMPH NODE METASTASIS; NONHUMAN; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SURVIVAL RATE; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; UROLOGY;

EID: 57849105427     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.07.025     Document Type: Review

References (43)

1. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
2. Pilepich M.V., Krall J.M., al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45 (1995) 616-623
3. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 79 (1997) 235-246
4. Messing E.M., Manola J., Yao J., et al. Eastern Cooperative Oncology Group study EST 3886. Immediate vs. deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
5. Studer U.E., Hauri D., Hanselmann S., et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: Results of the randomized trial SAKK 08/88. J Clin Oncol 22 (2004) 4109-4118
6. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Changes in body composition during androgen blockade for prostate cancer. J Clin Endocrinol Metab 87 (2002) 599-603
7. Smith M.R., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 (2006) 1305-1308
8. Lee H., McGovern K., Finkelstein J.S., et al. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Cancer 15 (2005) 1633-1637
9. Smith M.R., Lee H., Fallon M.A., et al. Adipocytes, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71 (2008) 318-322
10. Smith M.R., Lee H., McGovern F., et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer 112 (2008) 2188-2194
11. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
12. Dockery F., Bulprit C.J., Agarwal S., et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinemia. Aging Male 5 (2002) 195-201
13. Yannucci J., Manola J., Garnick M.B., et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 176 (2006) 520-525
14. Oefelein M.G., Ricchiuti V., Conrad W., et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 (2002) 1005-1007
15. Noble R.L. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 37 (1977) 82-94
16. Sato N., Gleave M.E., Bruchovsky N., et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Molec Biol 58 (1996) 139-146
17. Bruchovsky N., Rennie P.S., Coldman A.J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990) 2275-2282
18. Bruchovsky N., Klotz L.H., Sadar M.D., et al. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol 4 (2000) 191-199
19. Calais-da Silva F., Bono A., Whelan P., et al. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group. Oncology 65 Suppl 1 (2003) 24-28
20. Bruchovsky N., Klotz L., Crook J., et al. Locally advanced prostate cancer-biochemical results from a prospective Phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109 (2007) 858-867
21. Bruchovsky N., Klotz L., Crook J., et al. Final results of the Canadian prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters. Cancer 107 (2006) 389-395
22. Foulds L. Neoplastic Development 1 (1969), Academic Press, New York
23. Goldie J.H., and Coldman A.J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 (1979) 1727
24. Isaacs J.T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5 (1984) 1-17
25. So A.I., Bowden M., and Gleave M. Effect of time of castration and tumor volume on time to androgen-independent recurrence in Shionogi tumors. BJU Int 93 (2004) 845-850
26. Iversen P., Johansson J.E., Lodding P., et al., Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) vs. placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 172 (2004) 1871-1876
27. Smith M.R. Androgen deprivation therapy for prostate cancer: New concepts and concerns. Curr Opin Endocrinol Diabetes Obes 14 (2007) 247-254
28. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nature Rev 1 (2001) 34-45
29. Akakura K., Bruchovsky N., Goldenberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate specific antigen. Cancer 71 (1993) 2782-2790
30. Thalmann G.N., Anezinis P.E., Chang S.H., et al. Androgen-independent cancer progression and bone metastasis in the LNCaP Model of human prostate cancer. Cancer Res 54 (1994) 2577-2581
31. Umekita Y., Hiipakka R.A., Kokontis J.M., et al. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93 (1996) 11802-11807
32. Zhou H.Y.E., Chang S.-H., Chen B.-Q., et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93 (1996) 15152-15157
33. Russo P., Liguori G., Heston W.D.W., et al. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res 47 (1987) 5967-5970
34. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 45 (1995) 839-845
35. Hurtado-Coll A., Goldenberg S.L., Gleave M.E., et al. Intermittent androgen suppression in prostate cancer: The Canadian experience. Urology 60 3 Suppl 1 (2002) 52-56
36. Higano C.S., Ellis W., Russell K., et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer. A pilot study. Urology 48 (1996) 800-804
37. Grossfeld G.D., Small E.J., Lubeck D.P., et al. Androgen deprivation therapy for patients with clinically localized (Stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology 58 2 Suppl 1 (2001) 56-64
38. Shaw G.L., Wilson P., Cuzick J., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: A meta-analysis of 1446 patients. BJU Int 99 (2007) 1056-1065
39. Hussain M., Tangen C.M., Higano C., et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
40. Albrecht W., Collette L., Fava C., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study. Eur Urol 44 (2003) 505-511
41. Bruchovsky N., Klotz L., Crook J., et al. Quality of life, morbidity, and mortality results of a prospective Phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer 6 (2008) 46-52
42. Spry N.A., Kristjanson L., Hooton B., et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 42 (2006) 1083-1092
43. Sato N., Akakura K., Isaka S., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter study. Urology 64 (2004) 341-345